PORT: A Randomized, Cross-over, Phase 2 Study of Melflufen Peripheral versus Central Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma
Although recent therapeutic advances have significantly improved survival among patients with multiple myeloma,1 it is still considered to be an incurable disease for the majority of patients. With current therapeutic practice with triplet or quadruplet therapies recommended both at initial treatment and in later lines,2,3 patients at second or later relapses are being increasingly refractory to multiple classes of agents.4 Additionally, outcomes for patients with triple-refractory disease remain poor.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Ludek Pour, Ilina Micheva, Ganna Usenko, Gabor Mikala, Tamas Masszi, Kameliya Simeonova, Marcus Thuresson, Gunilla Huledal, Stefan Norin, Nicolaas A. Bakker, Jiri Minarik Tags: Original Study Source Type: research